person · Reporting owner

SIEGALL CLAY B

Disclosed activity across 8 companies

Tapewire entity: 28602
SEC CIK: 0001167496

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Immunome Inc.IMNM · Entity 4219	Director · President and CEO	July 23, 2026	July 27, 2026
Nurix Therapeutics, Inc.NRIX · Entity 1156	Director	May 05, 2022	May 06, 2022
SYNLOGIC, INC.MIRN · Entity 7801	Director	June 29, 2016	September 06, 2016
Seagen Inc.SGEN · Entity 13956	Director · President & CEO	May 12, 2022	May 13, 2022
Shattuck Labs, Inc.STTK · Entity 5224	Director	June 09, 2026	June 11, 2026
Ultragenyx Pharmaceutical Inc.RARE · Entity 4337	Director	August 07, 2020	August 11, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Immunome Inc.

Report date July 23, 2026 · Filed July 27, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	870,704	Reported balance After 2026-07-23 transaction · row 1 1 source row Row 1 · 2026-07-23 · Grant · Acquired 180,000 · Balance 870,704 F1: Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.01 · Expires 2036-07-22	Direct	360,000	Reported balance After 2026-07-23 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-07-23 · Grant · Acquired 360,000 · Balance 360,000 F2: 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.

F2: 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.

Nurix Therapeutics, Inc.

Report date May 05, 2022 · Filed May 06, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.39 · Expires 2032-05-04	Direct	17,500	Reported balance After 2022-05-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-05-05 · Grant · Acquired 17,500 · Balance 17,500 F1: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 5, 2023, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 5, 2023, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

SYNLOGIC, INC.

Report date June 29, 2016 · Filed September 06, 2016

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.74 · Expires 2026-06-29	Direct	10,000	Reported balance After 2016-06-29 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2016-06-29 · Grant · Acquired 10,000 · Balance 10,000 F1: The option vests and become exercisable in full on the earlier of (A) June 29, 2017 or (B) immediately prior to the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests and become exercisable in full on the earlier of (A) June 29, 2017 or (B) immediately prior to the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date.

Seagen Inc.

Report date May 12, 2022 · Filed May 13, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	666,060	Last balance in matching sequence After 2022-05-12 transaction · row 4 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 4 source rows Row 1 · 2022-05-12 · Exercise / conversion · Acquired 6,450 · Balance 672,510 F1: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Row 2 · 2022-05-12 · Sale · Disposed 6,450 · Balance 666,060 F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3: Reflects sales of common stock executed in multiple transactions at prices ranging from $126.00 to $126.55. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Row 3 · 2022-05-12 · Exercise / conversion · Acquired 10,593 · Balance 676,653 F1: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Row 4 · 2022-05-12 · Sale · Disposed 10,593 · Balance 666,060 F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4: Reflects sales of common stock executed in multiple transactions at prices ranging from $125.00 to $125.99. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.10 · Expires 2022-08-20	Direct	61,722	Reported balance After 2022-05-12 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-05-12 · Exercise / conversion · Disposed 6,450 · Balance 61,722 F5: Options vested at a rate of 25% on 8/20/13 and monthly thereafter until all the options were fully vested on 8/20/16.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.10 · Expires 2022-08-20	Direct	51,129	Reported balance After 2022-05-12 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-05-12 · Exercise / conversion · Disposed 10,593 · Balance 51,129 F5: Options vested at a rate of 25% on 8/20/13 and monthly thereafter until all the options were fully vested on 8/20/16.

Filing footnotes · ownership attribution and instrument terms

F1: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.

F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3: Reflects sales of common stock executed in multiple transactions at prices ranging from $126.00 to $126.55. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F4: Reflects sales of common stock executed in multiple transactions at prices ranging from $125.00 to $125.99. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F5: Options vested at a rate of 25% on 8/20/13 and monthly thereafter until all the options were fully vested on 8/20/16.

Shattuck Labs, Inc.

Report date June 09, 2026 · Filed June 11, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	318,608	Reported balance After 2026-06-09 transaction · row 1 1 source row Row 1 · 2026-06-09 · Purchase · Acquired 62,500 · Balance 318,608 F1: Represents shares of the Issuer's common stock purchased in connection with the Issuer's underwritten offering, which closed on June 11, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of the Issuer's common stock purchased in connection with the Issuer's underwritten offering, which closed on June 11, 2026.

Ultragenyx Pharmaceutical Inc.

Report date August 07, 2020 · Filed August 11, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	18,204	Reported balance After 2020-08-07 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2020-08-07 · Exercise / conversion · Acquired 5,904 · Balance 18,204
Common StockSEC Table I · non-derivative	Direct	35,704	Reported balance After 2020-08-07 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2020-08-07 · Exercise / conversion · Acquired 17,500 · Balance 35,704
Common StockSEC Table I · non-derivative	Direct	12,300	Reported balance After 2020-08-07 transaction · row 3 Account or security details depend on footnotes; rows are not merged. 1 source row Row 3 · 2020-08-07 · Sale · Disposed 23,404 · Balance 12,300 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.00 to $87.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Common StockSEC Table I · non-derivative	Direct	2,550	Reported balance After 2020-08-10 transaction · row 4 Account or security details depend on footnotes; rows are not merged. 1 source row Row 4 · 2020-08-10 · Sale · Disposed 9,750 · Balance 2,550 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.00 to $85.12 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Common StockSEC Table I · non-derivative	Direct	4,146	Reported balance After 2020-08-10 transaction · row 5 Account or security details depend on footnotes; rows are not merged. 1 source row Row 5 · 2020-08-10 · Exercise / conversion · Acquired 1,596 · Balance 4,146
Common StockSEC Table I · non-derivative	Direct	2,550	Reported balance After 2020-08-10 transaction · row 6 Account or security details depend on footnotes; rows are not merged. 1 source row Row 6 · 2020-08-10 · Sale · Disposed 1,596 · Balance 2,550 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.00 to $85.06 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.37 · Expires 2024-07-09	Direct	1,596	Reported balance After 2020-08-07 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-08-07 · Exercise / conversion · Disposed 5,904 · Balance 1,596 F5: The option vested in full on June 18, 2015.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.00 · Expires 2024-01-29	Direct	0	Reported balance After 2020-08-07 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-08-07 · Exercise / conversion · Disposed 17,500 · Balance 0 F6: The option vested with respect to 1/36th of the shares monthly such that the option fully vested on January 30, 2017.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.37 · Expires 2024-07-09	Direct	0	Reported balance After 2020-08-10 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2020-08-10 · Exercise / conversion · Disposed 1,596 · Balance 0 F5: The option vested in full on June 18, 2015.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.00 to $87.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.00 to $85.12 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.00 to $85.06 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

F5: The option vested in full on June 18, 2015.

F6: The option vested with respect to 1/36th of the shares monthly such that the option fully vested on January 30, 2017.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ALDER BIOPHARMACEUTICALS INC

Report date October 22, 2019 · Filed October 24, 2019

Section 16 reporting ended · disclosed 2019-10-24. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2019-10-22 transaction · row 1 1 source row Row 1 · 2019-10-22 · Other · Disposed 31,714 · Balance 0 F1: On September 16, 2019, the Reporting Person entered into a Tender and Support (the "Support Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC, Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser") and certain other securityholders of Issuer, pursuant to which the Reporting Person agreed to tender all shares of the Issuer's Common Stock, Class A-1 Convertible Preferred Stock or shares of Common Stock underlying stock options, as the case may be, held by Reporting Person to Purchaser (the "Tender Offer"). On October 22, 2019, Purchaser accepted the Tender Offer. F2: The Reporting Person will also receive one non-transferable contingent value right for each share held, which will entitle them to receive up to an additional $2.00 per share upon achievement of a milestone.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.46 · Expires 2020-02-25	Direct	Reported balance After 2019-10-22 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-10-22 · Disposition to issuer · Disposed 6,363 · Balance 0 F3: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F4: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of February 26, 2010 (the "2010 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2010 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2010 Vesting Commencement Date. The shares subject to this option are fully vested as of the date hereof. F5: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.96 · Expires 2021-05-09	Direct	Reported balance After 2019-10-22 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-10-22 · Disposition to issuer · Disposed 6,363 · Balance 0 F3: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F5: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F6: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2011 (the "2011 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2011 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2011 Vesting Commencement Date. The shares subject to this option are fully vested as of the date hereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.47 · Expires 2023-03-12	Direct	Reported balance After 2019-10-22 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-10-22 · Disposition to issuer · Disposed 6,363 · Balance 0 F3: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F5: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F7: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2012 (the "2012 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2012 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2012 Vesting Commencement Date. The shares subject to this option are fully vested as of the date hereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.47 · Expires 2023-03-12	Direct	Reported balance After 2019-10-22 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-10-22 · Disposition to issuer · Disposed 6,363 · Balance 0 F3: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F5: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F8: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2013 (the "2013 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2013 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2013 Vesting Commencement Date. The shares subject to this option are fully vested as of the date hereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.33 · Expires 2024-01-08	Direct	Reported balance After 2019-10-22 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2019-10-22 · Disposition to issuer · Disposed 6,363 · Balance 0 F3: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F5: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F9: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2014 (the "2014 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2014 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2014 Vesting Commencement Date. The shares subject to this option are fully vested as of the date hereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.66 · Expires 2025-05-18	Direct	Reported balance After 2019-10-22 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2019-10-22 · Disposition to issuer · Disposed 6,350 · Balance 0 F3: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F10: The shares subject to this option shall fully vest and become exercisable on the date of the 2016 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof. F11: The shares subject to this option, whether or not vested, were cancelled at the Effective Time without any consideration payable therefor.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.26 · Expires 2026-05-25	Direct	Reported balance After 2019-10-22 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2019-10-22 · Disposition to issuer · Disposed 15,000 · Balance 0 F3: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F11: The shares subject to this option, whether or not vested, were cancelled at the Effective Time without any consideration payable therefor. F12: The shares subject to this option shall fully vest and become exercisable on the date of the 2017 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.90 · Expires 2027-05-23	Direct	Reported balance After 2019-10-22 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2019-10-22 · Disposition to issuer · Disposed 15,000 · Balance 0 F3: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F5: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F13: The shares subject to this option shall fully vest and become exercisable on the date of the 2018 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.50 · Expires 2028-05-22	Direct	Reported balance After 2019-10-22 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2019-10-22 · Disposition to issuer · Disposed 15,000 · Balance 0 F3: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F5: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F14: The shares subject to this option shall fully vest and become exercisable on the date of the 2019 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.01 · Expires 2029-05-22	Direct	Reported balance After 2019-10-22 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2019-10-22 · Disposition to issuer · Disposed 22,500 · Balance 0 F3: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F5: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F15: The shares subject to this option shall fully vest and become exercisable on the date of the 2020 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date.

Filing footnotes · ownership attribution and instrument terms

F1: On September 16, 2019, the Reporting Person entered into a Tender and Support (the "Support Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC, Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser") and certain other securityholders of Issuer, pursuant to which the Reporting Person agreed to tender all shares of the Issuer's Common Stock, Class A-1 Convertible Preferred Stock or shares of Common Stock underlying stock options, as the case may be, held by Reporting Person to Purchaser (the "Tender Offer"). On October 22, 2019, Purchaser accepted the Tender Offer.

F2: The Reporting Person will also receive one non-transferable contingent value right for each share held, which will entitle them to receive up to an additional $2.00 per share upon achievement of a milestone.

F3: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck.

F4: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of February 26, 2010 (the "2010 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2010 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2010 Vesting Commencement Date. The shares subject to this option are fully vested as of the date hereof.

F5: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone.

F6: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2011 (the "2011 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2011 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2011 Vesting Commencement Date. The shares subject to this option are fully vested as of the date hereof.

F7: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2012 (the "2012 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2012 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2012 Vesting Commencement Date. The shares subject to this option are fully vested as of the date hereof.

F8: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2013 (the "2013 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2013 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2013 Vesting Commencement Date. The shares subject to this option are fully vested as of the date hereof.

F9: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2014 (the "2014 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2014 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2014 Vesting Commencement Date. The shares subject to this option are fully vested as of the date hereof.

F10: The shares subject to this option shall fully vest and become exercisable on the date of the 2016 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof.

F11: The shares subject to this option, whether or not vested, were cancelled at the Effective Time without any consideration payable therefor.

F12: The shares subject to this option shall fully vest and become exercisable on the date of the 2017 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof.

F13: The shares subject to this option shall fully vest and become exercisable on the date of the 2018 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof.

F14: The shares subject to this option shall fully vest and become exercisable on the date of the 2019 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof.

F15: The shares subject to this option shall fully vest and become exercisable on the date of the 2020 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date.

Tourmaline Bio, Inc.

Report date October 28, 2025 · Filed October 28, 2025

Section 16 reporting ended · disclosed 2025-10-28. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.55	Direct	Reported balance After 2025-10-28 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-10-28 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration"). F2: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.91	Direct	Reported balance After 2025-10-28 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-10-28 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration"). F2: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.73	Direct	Reported balance After 2025-10-28 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-10-28 · Disposition to issuer · Disposed 16,800 · Balance 0 F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration"). F2: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration").

F2: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
April 07, 2022 Filed Apr 8, 2022 21:41 UTC	Seagen Inc. SGEN · Entity 13956	SaleCommon Stock	3,828	$155.83	$596,517.24	Disclosure SEC source: 0000899243-22-014397 · doc4.xml · nonDerivative · entry 10 SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 667,945 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $155.14 to $156.13. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
April 07, 2022 Filed Apr 8, 2022 21:41 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionCommon Stock	3,828	$26.10	$99,910.80	Disclosure SEC source: 0000899243-22-014397 · doc4.xml · nonDerivative · entry 9 SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 671,773 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
April 07, 2022 Filed Apr 8, 2022 21:41 UTC	Seagen Inc. SGEN · Entity 13956	SaleCommon Stock	2,400	$154.36	$370,464.00	Disclosure SEC source: 0000899243-22-014397 · doc4.xml · nonDerivative · entry 8 SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 667,945 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $154.03 to $154.97. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
April 07, 2022 Filed Apr 8, 2022 21:41 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionCommon Stock	2,400	$26.10	$62,640.00	Disclosure SEC source: 0000899243-22-014397 · doc4.xml · nonDerivative · entry 7 SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 670,345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
April 07, 2022 Filed Apr 8, 2022 21:41 UTC	Seagen Inc. SGEN · Entity 13956	SaleCommon Stock	4,692	$153.38	$719,658.96	Disclosure SEC source: 0000899243-22-014397 · doc4.xml · nonDerivative · entry 6 SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 667,945 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $153.00 to $153.94. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
April 07, 2022 Filed Apr 8, 2022 21:41 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionCommon Stock	4,692	$26.10	$122,461.20	Disclosure SEC source: 0000899243-22-014397 · doc4.xml · nonDerivative · entry 5 SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 672,637 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
April 07, 2022 Filed Apr 8, 2022 21:41 UTC	Seagen Inc. SGEN · Entity 13956	SaleCommon Stock	2,100	$152.59	$320,439.00	Disclosure SEC source: 0000899243-22-014397 · doc4.xml · nonDerivative · entry 4 SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 667,945 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $151.98 to $152.92. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
April 07, 2022 Filed Apr 8, 2022 21:41 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionCommon Stock	2,100	$26.10	$54,810.00	Disclosure SEC source: 0000899243-22-014397 · doc4.xml · nonDerivative · entry 3 SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 670,045 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
April 07, 2022 Filed Apr 8, 2022 21:41 UTC	Seagen Inc. SGEN · Entity 13956	SaleCommon Stock	1,649	$151.42	$249,691.58	Disclosure SEC source: 0000899243-22-014397 · doc4.xml · nonDerivative · entry 2 SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 667,945 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $150.90 to $151.86. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
April 07, 2022 Filed Apr 8, 2022 21:41 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionCommon Stock	1,649	$26.10	$43,038.90	Disclosure SEC source: 0000899243-22-014397 · doc4.xml · nonDerivative · entry 1 SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 669,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
March 07, 2022 Filed Mar 9, 2022 19:42 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	4,000	$0.00 Strike: $26.10	$0.00	Disclosure SEC source: 0001203311-22-000018 · edgardoc.xml · derivative · entry 15 SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,215 Underlying: Common Stock · 4,000 shares Expires 2022-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Options vested at a rate of 25% on 8/20/13 and monthly thereafter until all the options were fully vested on 8/20/16. Read SEC document
March 07, 2022 Filed Mar 9, 2022 19:42 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	6,643	$0.00 Strike: $26.10	$0.00	Disclosure SEC source: 0001203311-22-000018 · edgardoc.xml · derivative · entry 14 SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,215 Underlying: Common Stock · 6,643 shares Expires 2022-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Options vested at a rate of 25% on 8/20/13 and monthly thereafter until all the options were fully vested on 8/20/16. Read SEC document
March 07, 2022 Filed Mar 9, 2022 19:42 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	2,400	$0.00 Strike: $26.10	$0.00	Disclosure SEC source: 0001203311-22-000018 · edgardoc.xml · derivative · entry 13 SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,858 Underlying: Common Stock · 2,400 shares Expires 2022-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Options vested at a rate of 25% on 8/20/13 and monthly thereafter until all the options were fully vested on 8/20/16. Read SEC document
March 07, 2022 Filed Mar 9, 2022 19:42 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	3,900	$0.00 Strike: $26.10	$0.00	Disclosure SEC source: 0001203311-22-000018 · edgardoc.xml · derivative · entry 12 SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,258 Underlying: Common Stock · 3,900 shares Expires 2022-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Options vested at a rate of 25% on 8/20/13 and monthly thereafter until all the options were fully vested on 8/20/16. Read SEC document
March 07, 2022 Filed Mar 9, 2022 19:42 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	100	$0.00 Strike: $26.10	$0.00	Disclosure SEC source: 0001203311-22-000018 · edgardoc.xml · derivative · entry 11 SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,158 Underlying: Common Stock · 100 shares Expires 2022-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Options vested at a rate of 25% on 8/20/13 and monthly thereafter until all the options were fully vested on 8/20/16. Read SEC document
March 07, 2022 Filed Mar 9, 2022 19:42 UTC	Seagen Inc. SGEN · Entity 13956	SaleCommon Stock	4,000	$135.62	$542,480.00	Disclosure SEC source: 0001203311-22-000018 · edgardoc.xml · nonDerivative · entry 10 SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 667,945 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $135.28 to $136.25. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
March 07, 2022 Filed Mar 9, 2022 19:42 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionCommon Stock	4,000	$26.10	$104,400.00	Disclosure SEC source: 0001203311-22-000018 · edgardoc.xml · nonDerivative · entry 9 SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 671,945 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
March 07, 2022 Filed Mar 9, 2022 19:42 UTC	Seagen Inc. SGEN · Entity 13956	SaleCommon Stock	6,643	$134.74	$895,077.82	Disclosure SEC source: 0001203311-22-000018 · edgardoc.xml · nonDerivative · entry 8 SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 667,945 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $134.26 to $135.25. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
March 07, 2022 Filed Mar 9, 2022 19:42 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionCommon Stock	6,643	$26.10	$173,382.30	Disclosure SEC source: 0001203311-22-000018 · edgardoc.xml · nonDerivative · entry 7 SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 674,588 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
March 07, 2022 Filed Mar 9, 2022 19:42 UTC	Seagen Inc. SGEN · Entity 13956	SaleCommon Stock	2,400	$133.69	$320,856.00	Disclosure SEC source: 0001203311-22-000018 · edgardoc.xml · nonDerivative · entry 6 SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 667,945 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $133.16 to $134.09. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
March 07, 2022 Filed Mar 9, 2022 19:42 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionCommon Stock	2,400	$26.10	$62,640.00	Disclosure SEC source: 0001203311-22-000018 · edgardoc.xml · nonDerivative · entry 5 SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 670,345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
March 07, 2022 Filed Mar 9, 2022 19:42 UTC	Seagen Inc. SGEN · Entity 13956	SaleCommon Stock	3,900	$132.72	$517,608.00	Disclosure SEC source: 0001203311-22-000018 · edgardoc.xml · nonDerivative · entry 4 SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 667,945 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $132.15 to $133.14. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
March 07, 2022 Filed Mar 9, 2022 19:42 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionCommon Stock	3,900	$26.10	$101,790.00	Disclosure SEC source: 0001203311-22-000018 · edgardoc.xml · nonDerivative · entry 3 SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 671,845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
March 07, 2022 Filed Mar 9, 2022 19:42 UTC	Seagen Inc. SGEN · Entity 13956	SaleCommon Stock	100	$136.33	$13,633.00	Disclosure SEC source: 0001203311-22-000018 · edgardoc.xml · nonDerivative · entry 2 SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 667,945 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
March 07, 2022 Filed Mar 9, 2022 19:42 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionCommon Stock	100	$26.10	$2,610.00	Disclosure SEC source: 0001203311-22-000018 · edgardoc.xml · nonDerivative · entry 1 SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 668,045 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
February 07, 2022 Filed Feb 9, 2022 19:02 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	300	$0.00 Strike: $26.10	$0.00	Disclosure SEC source: 0001203311-22-000014 · edgardoc.xml · derivative · entry 15 SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,258 Underlying: Common Stock · 300 shares Expires 2022-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Options vested at a rate of 25% on 8/20/13 and monthly thereafter until all the options were fully vested on 8/20/16. Read SEC document
February 07, 2022 Filed Feb 9, 2022 19:02 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	4,084	$0.00 Strike: $26.10	$0.00	Disclosure SEC source: 0001203311-22-000014 · edgardoc.xml · derivative · entry 14 SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,558 Underlying: Common Stock · 4,084 shares Expires 2022-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Options vested at a rate of 25% on 8/20/13 and monthly thereafter until all the options were fully vested on 8/20/16. Read SEC document
February 07, 2022 Filed Feb 9, 2022 19:02 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	8,985	$0.00 Strike: $26.10	$0.00	Disclosure SEC source: 0001203311-22-000014 · edgardoc.xml · derivative · entry 13 SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,642 Underlying: Common Stock · 8,985 shares Expires 2022-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Options vested at a rate of 25% on 8/20/13 and monthly thereafter until all the options were fully vested on 8/20/16. Read SEC document
February 07, 2022 Filed Feb 9, 2022 19:02 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	3,574	$0.00 Strike: $26.10	$0.00	Disclosure SEC source: 0001203311-22-000014 · edgardoc.xml · derivative · entry 12 SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,627 Underlying: Common Stock · 3,574 shares Expires 2022-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Options vested at a rate of 25% on 8/20/13 and monthly thereafter until all the options were fully vested on 8/20/16. Read SEC document
February 07, 2022 Filed Feb 9, 2022 19:02 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	100	$0.00 Strike: $26.10	$0.00	Disclosure SEC source: 0001203311-22-000014 · edgardoc.xml · derivative · entry 11 SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,201 Underlying: Common Stock · 100 shares Expires 2022-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Options vested at a rate of 25% on 8/20/13 and monthly thereafter until all the options were fully vested on 8/20/16. Read SEC document
February 07, 2022 Filed Feb 9, 2022 19:02 UTC	Seagen Inc. SGEN · Entity 13956	SaleCommon Stock	300	$141.56	$42,468.00	Disclosure SEC source: 0001203311-22-000014 · edgardoc.xml · nonDerivative · entry 10 SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 667,945 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $141.40 to $141.78. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
February 07, 2022 Filed Feb 9, 2022 19:02 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionCommon Stock	300	$26.10	$7,830.00	Disclosure SEC source: 0001203311-22-000014 · edgardoc.xml · nonDerivative · entry 9 SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 668,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
February 07, 2022 Filed Feb 9, 2022 19:02 UTC	Seagen Inc. SGEN · Entity 13956	SaleCommon Stock	4,084	$140.83	$575,149.72	Disclosure SEC source: 0001203311-22-000014 · edgardoc.xml · nonDerivative · entry 8 SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 667,945 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $140.36 to $141.32. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
February 07, 2022 Filed Feb 9, 2022 19:02 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionCommon Stock	4,084	$26.10	$106,592.40	Disclosure SEC source: 0001203311-22-000014 · edgardoc.xml · nonDerivative · entry 7 SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 672,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
February 07, 2022 Filed Feb 9, 2022 19:02 UTC	Seagen Inc. SGEN · Entity 13956	SaleCommon Stock	8,985	$139.96	$1,257,540.60	Disclosure SEC source: 0001203311-22-000014 · edgardoc.xml · nonDerivative · entry 6 SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 667,945 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $139.36 to $140.35. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
February 07, 2022 Filed Feb 9, 2022 19:02 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionCommon Stock	8,985	$26.10	$234,508.50	Disclosure SEC source: 0001203311-22-000014 · edgardoc.xml · nonDerivative · entry 5 SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 676,930 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
February 07, 2022 Filed Feb 9, 2022 19:02 UTC	Seagen Inc. SGEN · Entity 13956	SaleCommon Stock	3,574	$138.97	$496,678.78	Disclosure SEC source: 0001203311-22-000014 · edgardoc.xml · nonDerivative · entry 4 SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 667,945 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $138.36 to $139.35. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
February 07, 2022 Filed Feb 9, 2022 19:02 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionCommon Stock	3,574	$26.10	$93,281.40	Disclosure SEC source: 0001203311-22-000014 · edgardoc.xml · nonDerivative · entry 3 SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 671,519 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
February 07, 2022 Filed Feb 9, 2022 19:02 UTC	Seagen Inc. SGEN · Entity 13956	SaleCommon Stock	100	$137.29	$13,729.00	Disclosure SEC source: 0001203311-22-000014 · edgardoc.xml · nonDerivative · entry 2 SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 667,945 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
February 07, 2022 Filed Feb 9, 2022 19:02 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionCommon Stock	100	$26.10	$2,610.00	Disclosure SEC source: 0001203311-22-000014 · edgardoc.xml · nonDerivative · entry 1 SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 668,045 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
January 07, 2022 Filed Jan 11, 2022 19:14 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	8,163	$0.00 Strike: $26.10	$0.00	Disclosure SEC source: 0001203311-22-000004 · edgardoc.xml · derivative · entry 12 SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,301 Underlying: Common Stock · 8,163 shares Expires 2022-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Options vested at a rate of 25% on 8/20/13 and monthly thereafter until all the options were fully vested on 8/20/16. Read SEC document
January 07, 2022 Filed Jan 11, 2022 19:14 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	4,560	$0.00 Strike: $26.10	$0.00	Disclosure SEC source: 0001203311-22-000004 · edgardoc.xml · derivative · entry 11 SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,464 Underlying: Common Stock · 4,560 shares Expires 2022-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Options vested at a rate of 25% on 8/20/13 and monthly thereafter until all the options were fully vested on 8/20/16. Read SEC document
January 07, 2022 Filed Jan 11, 2022 19:14 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	3,221	$0.00 Strike: $26.10	$0.00	Disclosure SEC source: 0001203311-22-000004 · edgardoc.xml · derivative · entry 10 SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,024 Underlying: Common Stock · 3,221 shares Expires 2022-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Options vested at a rate of 25% on 8/20/13 and monthly thereafter until all the options were fully vested on 8/20/16. Read SEC document
January 07, 2022 Filed Jan 11, 2022 19:14 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	1,100	$0.00 Strike: $26.10	$0.00	Disclosure SEC source: 0001203311-22-000004 · edgardoc.xml · derivative · entry 9 SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,245 Underlying: Common Stock · 1,100 shares Expires 2022-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Options vested at a rate of 25% on 8/20/13 and monthly thereafter until all the options were fully vested on 8/20/16. Read SEC document
January 07, 2022 Filed Jan 11, 2022 19:14 UTC	Seagen Inc. SGEN · Entity 13956	SaleCommon Stock	8,163	$143.91	$1,174,737.33	Disclosure SEC source: 0001203311-22-000004 · edgardoc.xml · nonDerivative · entry 8 SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 667,945 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $143.41 to $144.38. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
January 07, 2022 Filed Jan 11, 2022 19:14 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionCommon Stock	8,163	$26.10	$213,054.30	Disclosure SEC source: 0001203311-22-000004 · edgardoc.xml · nonDerivative · entry 7 SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 676,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
January 07, 2022 Filed Jan 11, 2022 19:14 UTC	Seagen Inc. SGEN · Entity 13956	SaleCommon Stock	4,560	$144.82	$660,379.20	Disclosure SEC source: 0001203311-22-000004 · edgardoc.xml · nonDerivative · entry 6 SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 667,945 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $144.41 to $145.36. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
January 07, 2022 Filed Jan 11, 2022 19:14 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionCommon Stock	4,560	$26.10	$119,016.00	Disclosure SEC source: 0001203311-22-000004 · edgardoc.xml · nonDerivative · entry 5 SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 672,505 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
January 07, 2022 Filed Jan 11, 2022 19:14 UTC	Seagen Inc. SGEN · Entity 13956	SaleCommon Stock	3,221	$145.84	$469,750.64	Disclosure SEC source: 0001203311-22-000004 · edgardoc.xml · nonDerivative · entry 4 SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 667,945 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $145.42 to $146.38. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
January 07, 2022 Filed Jan 11, 2022 19:14 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionCommon Stock	3,221	$26.10	$84,068.10	Disclosure SEC source: 0001203311-22-000004 · edgardoc.xml · nonDerivative · entry 3 SIEGALL CLAY B · CIK 0001167496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 671,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.